NasdaqGS:GLUEBiotechs
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive
Monte Rosa Therapeutics (GLUE) dosed the first patient in its MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer, building on earlier combination data with enzalutamide.
See our latest analysis for Monte Rosa Therapeutics.
The MRT-2359 update comes after a sharp 36.08% decline in the 30-day share price return and a 24.05% decline over 90 days, even as the 1-year total shareholder return of 211.78% and 3-year total...